Virus like nanoparticles: Display matters
Abstract
An efficacious way to avoid atleast a bunch of infections by microbes is to neutralize the microbial infection right at the very beginning. This is well achieved by vaccination against many infectious agents. While vaccine is available for many pathogenic micro-organisms, we are still struggling to achieve success to develop prophylactic strategies for many others. Most commonly vaccines are developed by attenuation/ inactivation of infectious agents or by using killed pathogens. Yet another variety of vaccines include the subunit vaccine. In this review a subcategory of subunit vaccine has been discussed where the viral surface antigens when displayed in a rigid multivalent fashion at high densities, induce very potent and robust neutralizing antibody response as a result of very strong and extensive cross-linking of B-cell receptors.
References
(URL:http://www.sciencedirect.com/science/article/pii/S0167569996100669)
2. Chackerian B, Lenz P, Lowy D R, Schiller J T (2002) Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J Immunol 169 6120–6126
(URL: http://www.jimmunol.org/content/169/11/6120.long)
3. Chackerian B, Lowy D R, Schiller J T (2001) Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J Clin Invest 108 415–423
(URL: http://www.jci.org/articles/view/11849)
4. Kanekiyo M, Wei C J, Yassine H M, McTamney P M, Boyington J C, Whittle J R, Rao S S, Kong W P, Wang L, Nabel G J (2013) Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499 (7456) 102-6
(URL:http://www.nature.com/nature/journal/v499/n7456/full/nature12202.html)
5. Kanekiyo M, Bu W, Joyce M G, Meng G, Whittle J R, Baxa U, Yamamoto T, Narpala S, Todd J P, Rao S S, McDermott A B, Koup R A, Rossmann M G, Mascola J R, Graham B S, Cohen J I, Nabel G J (2015) Rational design of an Epstein Barr Virus vaccine targeting the receptor-binding site. Cell 162(5):1090-100
(URL: http://www.sciencedirect.com/science/article/pii/S0092867415009599)
6. Kemp T J, Hildesheim A, Safaeian M, Dauner J G, Pan Y, Porras C, Schiller J T, Lowy D R, Herrero R, Pinto L A (2011) HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine 29 (11) 2011-4
(URL: http://www.sciencedirect.com/science/article/pii/S0264410X1100017X)
7. Schiller J T, Muller M (2015) Next generation prophylactic human papillomavirus vaccines. Lancet Oncol 16(5) e217-25
(URL: http://www.sciencedirect.com/science/article/pii/S1470204514711799)
8. Pastrana D V, Ray U, Magaldi T G, Schowalter R M, Çuburu N, Buck C B (2013) BK polyomavirus genotypes represent distinct serotypes with distinct entry tropism. J Virol 87(18) 10105-13
(URL: http://jvi.asm.org/cgi/pmidlookup?view=long&pmid=23843634)
9. Ray U, Cinque P, Gerevini S, Longo V, Lazzarin A, Schippling S, Martin R, Buck C B, Pastrana D V (2015) JC polyomavirus mutants escape antibody-mediated neutralization.Sci Transl Med 7(306) 306ra151
(URL: http://stm.sciencemag.org/cgi/pmidlookup?view=short&pmid=26400912)
10. Thrane S, Janitzek C M, Matondo S, Resende M, Gustavsson T, de Jongh W A, Clemmensen S, Roeffen W, van de Vegte-Bolmer M, van Gemert G J, Sauerwein R, Schiller J T, Nielsen M A, Theander T G, Salanti A, Sander A F (2016) Bacterial superglue enables easy development of efficient virus-like particle based vaccines. J Nanobiotechnology 14:30
(URL: http://jnanobiotechnology.biomedcentral.com/articles/10.1186/s12951-016-0181-1)
11. Zakeri B, et al. (2012) Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin. Proc Natl Acad Sci USA 109(12) E690–E697
(URL: http://www.pnas.org/content/109/12/E690.long)
